Development of Novel Targeted Drugs for Treatment of Liver Fibrosis
The aim is to develop the first targeted treatment for patients suffering from liver fibrosis (LF). The approach is based on a nanobody-drug-conjugate (NDC), targeted to hepatic stellate cells (HSC), by linking HSC-specific nanobodies to a fibrotic scar diminishing drug, using the proprietary Lx-linker, together called LxL-LF. DeFiber aims to select the best LxL-LF candidate based on in vitro and in vivo studies, and to develop complementary diagnostics, preparing for the (pre-)clinical phases.
2 063 160.00€
Pharmaceutical Products / Drugs
Drug delivery and other equipment (including kidney dialysis machines)